Navigation Links
Millipore Sues W.L. Gore & Associates for Patent Infringement
Date:7/10/2009

BILLERICA, Mass., July 10 /PRNewswire/ -- Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, including bioscience research and biopharmaceutical manufacturing, has filed a lawsuit in the United States District Court for the District of Massachusetts, against W.L. Gore & Associates for infringement of Millipore's patent rights under U.S. Patent No. 7,293,477, "Disposable, Pre-Sterilized Fluid Receptacle Sampling Device," by selling one or more of its STA-PURE(TM) samplers.

W.L. Gore's product competes with components of Millipore's NovaSeptum(R) sampling system for the pharmaceutical and biopharmaceutical manufacturing industries. The NovaSeptum sampling system is a sterile, disposable, completely enclosed sampling system for aseptic and sterile processes. Sampling is critical for biopharmaceutical manufacturing; an imprecise or false positive result can lead to batch loss and may also require repeat sampling and analysis at additional costs.

"This filing reflects our intention to vigorously defend our intellectual property, which is a fundamental component of the innovation we provide to our customers," says Jean-Paul Mangeolle, President of Millipore's Bioprocess Division.

According to Roland Heinrich, Vice President of Millipore's Process Monitoring Tools, "Millipore's NovaSeptum sampling system has broad industry acceptance. With our strong patent position, I am confident we will remain an industry pioneer in sampling systems."

In 2007, Millipore Corporation successfully asserted its U.S. Patent No. 6,779,575 in the U.S. District Court for the District of New Jersey against acts of infringement by Amesil, Inc., and obtained a consent judgment issued by the Court against Amesil. The subject of that lawsuit was also a product that competed with components of Millipore's NovaSeptum(R) sampling system. Amesil was acquired by W.L. Gore in 2007.

About Millipore

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, visit www.millipore.com.

ADVANCING LIFE SCIENCE TOGETHER(TM)

Research. Development. Production.

Safe Harbor Statement

Certain of the matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, failure to achieve design wins into our pharmaceutical and biotechnology customers' manufacturing design phase for a particular drug or vaccine; delay, suspension or termination of a customer's volume production; fluctuations in the timing of customers' orders; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of new therapeutics; limitations on cash flow for operations and investment due to debt service obligations; the inability to establish and maintain necessary product and process quality levels; reduced demand for cell culture products using bovine serum; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chromatography technology; risks relating to our concentration of principal manufacturing operations; the inability to successfully integrate acquired businesses; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.

Millipore and NovaSeptum are registered trademarks; and the "M" logo and ADVANCING LIFE SCIENCE TOGETHER are trademarks of Millipore Corporation.


'/>"/>
SOURCE Millipore Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Former Associates File Suit Against Univera: Dietary Supplement Company Accused of Intimidation, Bullying, and Unfair Trade Practices
2. Health Care Reform May Force U.S. Pharmaceutical Companies to Overhaul Sales Strategies, Says New Report From ZS Associates and eyeforpharma
3. Compressus Initiates Enterprise Workflow Management Implementation at Radiology Associates of Fox Valley
4. Infini Cosmetic Associates Offers Boomer Stimulus Packages to Offset Aging and Help Job Seekers Get a Fresh Start
5. Gullapalli & Associates Launches First-of-Its-Kind Patient Centered CME(TM) (PCCME(TM)) Service, Names Dora Ochsenbein Manager of Educational Planning
6. St. Cloud Orthopedic Associates to Partner with Surgical Care Affiliates
7. Bob Gold & Associates Steps Up as Marketing & PR Agency for Bay Harbor Podiatry Group
8. Lambert, Edwards & Associates Named Agency of Record for Aspirus, Inc.
9. Anthem Blue Cross Associates Volunteer to Help California Organizations During Second Annual Community Service Day
10. Anthem Blue Cross and Blue Shield Associates Volunteer to Help Wisconsin Organizations During Second Annual Community Service Day
11. Virginia Interventional and Vascular Associates Offers Alternative to Hysterectomy for Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: